Multicenter, open-label, phase 2 study of carboplatin plus MIRV followed by MIRV

• Research type

  Research Study

• Full title

  Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy

• IRAS ID

  1006060

• Contact name

  Melanie Pooler

• Contact email

  mel.pooler-mora@ergomedplc.com

• Sponsor organisation

  ImmunoGen, Inc.

• Clinicaltrials.gov Identifier

  NCT05456685

• Research summary

  Evaluation of cancers treatment using monoclonal antibodies “Mirvetuximab soravtansine”, in antibody-responder patients

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  23/SC/0048

• Date of REC Opinion

  22 Sep 2023

• REC opinion

  Further Information Favourable Opinion